Upadacitinib Shows Efficacy in Refractory Crohn's Disease - Medscape
This study reports that upadacitinib produced clinical responses and steroid-free remission in a majority of patients with refractory Crohn's disease at 12 weeks, which may be relevant for people who have not responded...